[0018] FIG. **29**: Gating strategy for Nectin-4 in Breast (T-47D and MDA-MB-468).

[0019] FIG. **30**: Gating strategy for Nectin-4 in NCI-H292 and NCI-H322.

[0020] FIGS. **31** and **32**: Gating strategy for Nectin-4 in NCI-H526 and HT1080, respectively.

[0021] FIGS. **33-37**: Gating strategy for Nectin-4 in Bladder cancer (HT1376; FIG. **33**), Breast cancer (MDA-MB-468; FIG. **34**), Colorectal cancer (HT-29; FIG. **35**A and HCT-116; FIG. **35**B), Lung cancer (A549; FIG. **36**A, NCI-H292; FIG. **36**B, NCI-H358; FIG. **36**C and NCI-526; FIG. **36**D), and Pancreas cancer (Panc02.13; FIG. **37**), respectively.

[0022] FIGS. **38-41**: Tumor volume traces after administering BCY8242, BCY8245, BCY8253, and BCY8255, respectively, to female Balb/c nude mice bearing A549 xenograft.

[0023] FIGS. **42-45**: Tumor volume traces after administering BCY8242, BCY8245, BCY8253, and BCY8255, respectively, to female Balb/c nude mice bearing HCT116 xenograft.

[0024] FIGS. **46-49**: Tumor volume traces after administering BCY8242, BCY8245, BCY8253, and BCY8255, respectively, to female CB17-SCID mice bearing HT-1376 xenograft.

[0025] FIGS. **50-53**: Tumor volume traces after administering BCY8242, BCY8245, BCY8253, and BCY8255, respectively, to female Balb/c nude mice bearing MDA-MB-468 xenograft.

[0026] FIGS. **54-57**: Tumor volume traces after administering BCY8242, BCY8245, BCY8253, and BCY8255, respectively, to female Balb/c nude mice bearing NCI-H292 xenograft.

[0027] FIGS. **58-59**: Tumor volume traces after administering BCY8245 and BCY8255, respectively, to female Balb/c nude mice bearing NCI-H526 xenograft. FIGS. **60-63**: Tumor volume traces after administering BCY8242, BCY8245, BCY8253, and BCY8255, respectively, to female Balb/c nude mice bearing Panc2.13 xenograft.

[0028] FIG. **64**: Tumor volume traces after administering BCY8245, BCY8781 or BCY8245 in combination with BCY8234 to female Balb/c nude mice bearing MDA-MB-468 xenograft.

[0029] FIG. **65**: Tumor volume traces after administering BCY8245 alone or BCY8245 in combination with BCY8234 to female Balb/c nude mice bearing MDA-MB-468 xenograft.

[0030] FIGS. **66-71**: Tumor volume traces in Lu-01-0412, LU-01-0007, CTG-1771, CTG-1171, CTG-1106, and CTG-0896 PDX xenografts.

[0031] FIG. **72**: BT8009 (i.e. BCY8245) efficacy correlates with expression CDX/PDX xenografts. Xenografts with little/no Nectin-4 expression show reduced tumour growth rate. Xenografts expressing Nectin-4 show regressions of tumour. Both PDX and CDX models are included in this analysis, values are collated from various reports.

[0032] FIG. **73**: MDA-MB-468 cells express Nectin-4 and show prolonged retention of MMAE in tumour.

[0033] FIG. **74**: HCS—Data analysis on MDA-MB-468 cell line.

DETAILED DESCRIPTION OF THE INVENTION

[0034] In one embodiment, said loop sequences comprise 3, 6, 7, 8 or 9 amino acids. In a further embodiment, said loop sequences comprise 3, 6, 7 or 9 amino acids. In a yet further embodiment, said loop sequences comprise 3 or 9 amino acids.

[0035] In a further embodiment, said loop sequences comprise three cysteine residues separated by two loop sequences one of which consists of 3 amino acids and the other of which consists of 9 amino acids.

[0036] In a further embodiment, said loop sequences comprise three cysteine residues separated by two loop sequences one of which consists of 3 amino acids and the other of which consists of 8 amino acids.

[0037] In a further embodiment, said loop sequences comprise three cysteine residues separated by two loop sequences one of which consists of 7 amino acids and the other of which consists of 3 amino acids.

[0038] In a further embodiment, said loop sequences comprise three cysteine residues separated by two loop sequences both of which consist of 6 amino acids.

[0039] In one embodiment, said peptide ligand comprises an amino acid sequence selected from:

(SEQ ID NO: 38)
C_i-P/A/Hyp-F/Y-G/A-C_{ii}-X_1-X_2-X_3-W/1-Nal/2-Nal-S/A-X_4-P-1/D/A-W/1-Nal/2-Nal-C_{iii};

(SEQ ID NO: 39)
C_i-W/A-P-L-D/S-S/D-Y-W-C_{ii}-X_5-R-I-C_{iii};

(SEQ ID NO: 40)
C_i-V-T-T-S-Y-D-C_{ii}-F/W-L/V-H/R/T-L-L/G-G/Q/H-C_{iii};

(SEQ ID NO: 41)
C_i-X_6-X_7-X_8-C_{ii}-X_9-X_{10}-X_{11}-X_{12}-X_{13}-X_{14}-X_{15}-X_{16}-X_{17}-C_{iii};
and

(SEQ ID NO: 42)
C_i-W/A/Y-P/A-L-D/S/A-S/D/P/A-Y-W/1-Nal-C_{ii}-X_5-R/HArg/A-I-C_{iii};

wherein:

[0040] X_1-X_5 represent any amino acid residue, including modified and non-natural amino acids; X_6 represents: Gly; Pro or a non-natural derivative of Pro selected from azetidine (Aze), hydroxyproline (HyP), 4-amino-proline (Pro (4NH)), oxazolidine-4-carboxylic acid (Oxa), octahydroindolecarboxylic acid (Oic) or 4,4-difluoroproline (4,4-DFP); Ala or a non-natural derivative of Ala selected from aminoisobutyric acid (Aib); or Sarcosine (Sar);

[0041] X_7 represents: Phe or a non-natural derivative of Phe selected from 3-methyl-phenylalanine (3MePhe), 4-methyl-phenylalanine (4MePhe), homophenylalanine (HPhe), 4,4-biphenylalanine 4,4-BPA) or 3,4-dihydroxyphenylalanine (DOPA); Tyr; or Ala or a non-natural derivative of Ala selected from 1-naphthylalanine (1-Nal), 2-naphthylalanine (2-Nal) or 2-pyridylalanine (2Pal);

[0042] X_8 represents: Gly; Ala; Asp; Lys or a non-natural derivative of Lys selected from acetyl-lysine (KAc or Lys (Ac)); Phe; Glu; Gln; Leu; Ser; Arg; or cysteic acid (Cya);

[0043] X_9 is either absent or represents: Met or a non-natural derivative of Met selected from methionine sulfone (Met(O2)); Gln or a non-natural derivative of Gln selected